A new study suggests that the benefits of prescribing anticoagulation drugs to certain older people outweigh the potential risks.

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

RECENT clinical reports have stressed beneficial effects resulting from the use of anticoagulant drugs in thrombosis of the basilar and carotid arteries1 2 3 4 and in ...

Background Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused ...

AstraZeneca's anticoagulant reversal agent Andexxa was ... if treatment with the drugs leads to life-threatening or uncontrolled bleeding complications. On the positive side, members of the ...

When an older adult with atrial fibrillation, or Afib, stops taking an anticoagulant, it raises their risk of stroke or heart attack more than risks of bleeding, according to a new report published ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent ...

Current treatments rely on anticoagulants such as direct oral anticoagulants ... in serious adverse events or discontinuations due to drug reactions. Injection-site reactions were also infrequent ...

“It has the added advantage of avoiding oral anticoagulation drugs and the risks associated with lifelong anticoagulation. In fact, most of our patients are not on any cardiac medications ...